Research & Development: Page 83
-
PharmaVoice Team/PharmaVoice
The Softer Side of R&D
Industry experts say the technical competencies of drug development have to be combined with the softer skills of change management and leadership ability. R&D leaders will have to work in global teams to manage the output from their partners. This will require highly trained technical specia...
By Denise Myshko • March 27, 2008 -
PharmaVoice Team/PharmaVoice
Proof of Concept
BENEFITS OF EXPLORATORY INDS In a guidance released in January 2006, the FDA laid out specific approaches for researchers George Mills, M.D., VP, medical imaging consulting, for Perceptive Informatics at Parexel International, agrees that an exploratory IND is an avenue to evaluate the preclinica...
By Denise Myshko • March 27, 2008 -
Explore the Trendline➔
Stock via Getty Images
TrendlineArtificial intelligence & machine learning
After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
UpFront
Milestones 20 YEARS OF DISCOVERY Pharmaceutical Research and Manufacturers of America (PhRMA) has marked the 20th anniversary of the Discoverers Award, the highest honor given by PhRMA to scientists who helped discover breakthrough medicines for patients suffering from disease. PhRMA presented th...
By PharmaVoice Team • March 27, 2008 -
PharmaVoice Team/PharmaVoice
Raise Your Voice — Letters
A Missing Link I just finished reading the March article, “Strengthening the Clinical Recruitment Chain,” and it seems to me that you forgot a crucial first step in the process you describe. This would be the establishment of a sound protocol that makes scientific sense and benefits the subject. ...
By PharmaVoice Team • March 27, 2008 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
Bogey and Bacall, Rogers and Hammerstein,Ben & Jerry,or closer to home John K. Smith, Thomas Beecham, and Mahlon Kline — great partners who made for great partnerships. In developing this issue, an inadvertent theme developed, one centered around the concept of partner ships. What makes them ...
By PharmaVoice Team • March 27, 2008 -
PharmaVoice Team/PharmaVoice
What's New
weaknesses of a product’s message,” says Howard Ziment, CEO.“What the Messagez approach does is qualify, or even eliminate, much of that debate so product directors and agencies can spend more time and energy being creative.” The Messagez approach involves several phases.First, it assures the cre...
By PharmaVoice Team • March 19, 2008 -
PharmaVoice Team/PharmaVoice
On the Calendar
September 1819,2003,Westin Princeton — Princeton,N.J. 2nd Annual Edetailing The Center for Business Intelligence’s eDetailing confer ence will provide an interactive forum to discuss how this innovative tool allows companies to access more physicians and ultimately increase sales. For more inform...
By PharmaVoice Team • March 19, 2008 -
PharmaVoice Team/PharmaVoice
PharmaTrax
76 S e p t e m b e r 200 3 PharmaVOICE Johnson & Johnson is TOP PHARMA COMPANY IN LONGTERM CARE Johnson & Johnson has been selected as the best overall pharmaceutical company by longte rm care (LTC) pharmacists participating in Verispan’s spring 2003 Nursing Home PharmacyProvider/Con sult...
By PharmaVoice Team • March 19, 2008 -
PharmaVoice Team/PharmaVoice
Joseph F. Donahue-Destined for Science
Destined for Science As one of the new breed of 40something business leaders, Joseph F. Donahue is bringing a multidiscipline skill set to help LION bioscience become the leader in improving research productivity within the lifesciences industry. BY KIM RIBBINK 64 S e p t e mb e r 2003 PharmaVOIC...
By Kim Ribbink • March 19, 2008 -
PharmaVoice Team/PharmaVoice
The Great Divide
58 S e p t e mb e r 2003 PharmaVOICE ALL TOO OFTEN MARKETING AND R&D ARE AT ODDS ON HOW TO BEST ALLOCATE RESOURCES TO SUPPORT THE PIPELINE.THIS DISCONNECT BETWEEN SALES AND SCIENCE THREATENS THE FUTURE OF THE PHARMACEUTICAL INDUSTRY. The GREATDivide IN AN EXCLUSIVETO PHARMAVOICE, MICHAEL MENA...
By PharmaVoice Team • March 19, 2008 -
PharmaVoice Team/PharmaVoice
A Temporary Solution
50 S e p t e mb e r 2003 PharmaVOICE clinical trial staffing A T E M P O R A R Y S O L U T I O N the days of temps as lowwage, lowstatus secretaries without benefits have passed. Now highly specialized — and often highly paid — scientists and oth ers involved in clinical research are joining the ...
By PharmaVoice Team • March 19, 2008 -
PharmaVoice Team/PharmaVoice
Opinions
8 S e p t e mb e r 2003 PharmaVOICE other incentives. It was only a matter of time before customer rewards led to increased demands from all business categories, includ ing pharmaceuticals and healthcare. Another trend in healthcare is the increasing portion of the healthcare bill being demanded ...
By PharmaVoice Team • March 18, 2008 -
PharmaVoice Team/PharmaVoice
Raise Your Voice — Letters
6 S e p t e m b e r 2003 PharmaVOICE RAISE your voice Few lessons learned I am writing to offer my feedback about the article “The Lessons of Greed” in the July 2003 issue of PharmaVOICE. As a clinicalresearch professional involved with ensuring the ethical conduct of clinical trials, I have clos...
By PharmaVoice Team • March 18, 2008 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
PUBLISHER Lisa Banket EDITOR Taren Grom CREATIVE DIRECTOR Marah Walsh DIRECTOR OF SALES Darlene Kwiatkowski MANAGING EDITOR Denise Myshko CONTRIBUTING EDITORS Elisabeth Pena Kim Ribbink Lynda Sears Copyright 2003 by PharmaLinx LLC, Titusville, NJ Printed in the U.S.A. Volume Three, Number Nine Ph...
By Taren Grom • March 18, 2008 -
PharmaVoice Team/PharmaVoice
Global Opportunities
According to Ernst & Young, the sheer volume and growing economic muscle of consumers in emerging markets provide powerful investment incentives for multinational companies (MNCs). In particular, current and projected growth rates for pharmaceutical markets in the BRIC countries and Mexico ex...
By Robin Robinson • March 2, 2008 -
PharmaVoice Team/PharmaVoice
Last Word
Alan C. Moses, M.D., is VP, Chief Medical Officer Worldwide, Novo Nordisk Inc. He has a broad and indepth background in diabetes research and specialization. Previously, Dr. Moses was Senior VP and Chief Medical Officer at the Joslin Diabetes Center and joined Novo Nordisk in April 2004 as Associ...
By PharmaVoice Team • March 2, 2008 -
PharmaVoice Team/PharmaVoice
Talent Pool
Pharma POOL Wendy KOUBA Wyeth Names Communications VP Wyeth, Madison, N.J., has promoted Wendy Kouba to VP, cor porate communications, from VP, communica tions, technical operations and product supply. In this new role, Ms. Kouba oversees the company’s global public relations and communications f...
By PharmaVoice Team • March 2, 2008 -
PharmaVoice Team/PharmaVoice
On the Calendar
March 1718 3rd Imaging in Preclinical &Clinical Drug Development San Diego For more information, contact Vivian Frankel, GTCBio, at 6262566405, email [email protected], or visit gtcbio.com. March 1718 The Inaugural U.S.Conference on Comparator Studies Doubletree Hotel,Philadelphia For...
By PharmaVoice Team • March 2, 2008 -
PharmaVoice Team/PharmaVoice
E-Media
NEW ELECTRONIC AND WEBBASED APPLICATIONS, SITES, AND TECHNOLOGIES Edge Dynamics has added a flexible desktop module within its Demand Management Suite that offers lifesciences manufacturers a way to easily monitor and analyze channel activity data for their products. The Edge Dynamics Demand Dash...
By PharmaVoice Team • March 2, 2008 -
PharmaVoice Team/PharmaVoice
What's New
WHAT’S NEW NEW HEALTHCARERELATED PRODUCTS, SERVICES, AND COMPANIES HealthEd Group has launched HealthEd Encore, which operates as a standalone agency, in response to increas ing client demand for educational patient marketing campaigns. HealthEd Encore offers a fullrange of ser vices, including c...
By PharmaVoice Team • March 2, 2008 -
PharmaVoice Team/PharmaVoice
PharmaTrax
Best practices in planning and targeting and conducting office calls, as well as management of relationships, samples, programs, and salesforces are explored. These include the use of automated for mulary data and thoughtleader information to develop sales messages that anticipate formulary restr...
By PharmaVoice Team • March 2, 2008 -
PharmaVoice Team/PharmaVoice
PharmaOutlet
Research collaborations can be a very useful adjunct to a company’s scientific investigations. They can expand their intellectual property portfolios, speed up the entry of molecules into the clinic, and possibly enhance their future revenue streams. In fact, there may be times when your company’...
By Dr. Stewart Lyman • March 2, 2008 -
PharmaVoice Team/PharmaVoice
A Woman's Heart
Women are six times more likely to die from heart attacks than breast cancer. Car diovascular diseases (CVD), particularly coronary heart disease (CHD) and stroke, remain the leading causes of death of women in America and most developed coun tries, with almost 39% of all female deaths in the Uni...
By Cynthia Borda • March 2, 2008 -
PharmaVoice Team/PharmaVoice
Strengthening the Clinical Recruitment Chain
W finding the right population within the right time frame means doing your homework, looking at feasibility data, modeling time frames, metrics, and budget parameters.” Negative press is another uncontrollable factor that can slow patient enrollment, par ticularly if a drug is pulled from the ma...
By Robin Robinson • Feb. 26, 2008 -
PharmaVoice Team/PharmaVoice
UpFront
DETAILING DUDS Rep Access Continues to Fall Based on a comprehensive telephone survey of 180,000 doctors, almost one fifth of U.S. officebased physicians refuse to see sales representatives from the drug and device industry at any time, according to SK&A Information Services. Another 22.7% of...
By PharmaVoice Team • Feb. 26, 2008
Previous
